Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): study protocol for a cluster-randomised controlled trial

Christin Richter, Almuth Berg, Steffen Fleischer, Sascha Köpke, Katrin Balzer, Eva-Maria Fick, Andreas Sönnichsen, Susanne Löscher, Horst Christian Vollmar, Burkhard Haastert, Andrea Icks, Charalabos-Markos Dintsios, Eva Mann, Ursula Wolf, Gabriele Meyer, Christin Richter, Almuth Berg, Steffen Fleischer, Sascha Köpke, Katrin Balzer, Eva-Maria Fick, Andreas Sönnichsen, Susanne Löscher, Horst Christian Vollmar, Burkhard Haastert, Andrea Icks, Charalabos-Markos Dintsios, Eva Mann, Ursula Wolf, Gabriele Meyer

Abstract

Background: The majority of nursing home residents with dementia experience behavioural and psychological symptoms like apathy, agitation, and anxiety. According to analyses of prescription prevalence in Germany, antipsychotic drugs are regularly prescribed as first-line treatment of neuropsychiatric symptoms in persons with dementia, although guidelines clearly prioritise non-pharmacological interventions. Frequently, antipsychotic drugs are prescribed for inappropriate reasons and for too long without regular reviewing. The use of antipsychotics is associated with adverse events like increased risk of falling, stroke, and mortality. The aim of the study is to investigate whether a person-centred care approach, successfully evaluated in nursing homes in the United Kingdom, can be implemented in German nursing homes and, in comparison with a control group, can result in a clinically relevant reduction of the proportion of residents with antipsychotic prescriptions.

Methods/design: The study is a cluster-randomised controlled trial comparing an intervention group (two-day initial training on person-centred care and ongoing training and support programme) with a control group. Both study groups will receive, as optimised usual care, a medication review by an experienced psychiatrist/geriatrician providing feedback to the prescribing physician. Overall, 36 nursing homes in East, North, and West Germany will be randomised. The primary outcome is the proportion of residents receiving at least one antipsychotic prescription (long-term medication) after 12 months of follow-up. Secondary outcomes are residents' quality of life, agitated behaviour, as well as safety parameters like falls and fall-related medical attention. A health economic evaluation and a process evaluation will be performed alongside the study.

Discussion: To improve care, a reduction of the current high prescription rate of antipsychotics in nursing homes by the intervention programme is expected.

Trial registration: ClinicalTrials.gov: NCT02295462.

Figures

Fig. 1
Fig. 1
Flow chart of EPCentCare

References

    1. Richter T, Mann E, Meyer G, Haastert B, Köpke S. Prevalence of psychotropic medication use among German and Austrian nursing home residents: a comparison of 3 cohorts. J Am Med Dir Assoc. 2012;13(187):e113. e187-187.
    1. Köpke S, Mühlhauser I, Gerlach A, Haut A, Haastert B, Möhler R, et al. Effect of a guideline-based multicomponent intervention on use of physical restraints in nursing homes: a randomized controlled trial. JAMA. 2012;307:2177–84. doi: 10.1001/jama.2012.4517.
    1. Meyer G, Köpke S, Haastert B, Mühlhauser I. Restraint use among nursing home residents: cross-sectional study and prospective cohort study. J Clin Nurs. 2009;18:981–90. doi: 10.1111/j.1365-2702.2008.02460.x.
    1. Meyer G, Köpke S, Haastert B, Mühlhauser I. Comparison of a fall risk assessment tool with nurses’ judgement alone: a cluster-randomised controlled trial. Age Ageing. 2009;38:417–23. doi: 10.1093/ageing/afp049.
    1. Balzer K, Butz S, Bentzel J, Boulkhemair D, Luhmann D. Medical specialist attendance in nursing homes. GMS Health Technol Assess. 2013;9:Doc02.
    1. Oborne CA, Hooper R, Li KC, Swift CG, Jackson SH. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing. 2002;31:435–9. doi: 10.1093/ageing/31.6.435.
    1. Margallo-Lana M, Swann A, O’Brien J, Fairbairn A, Reichelt K, Potkins D, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. 2001;16:39–44. doi: 10.1002/1099-1166(200101)16:1<39::AID-GPS269>;2-F.
    1. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:10–28. doi: 10.1177/1533317510390351.
    1. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627–32. doi: 10.1503/cmaj.061250.
    1. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69. doi: 10.1001/jama.2011.1360.
    1. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227. doi: 10.1136/bmj.a1227.
    1. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596–608. doi: 10.1001/jama.293.5.596.
    1. Rigler SK, Shireman TI, Cook-Wiens GJ, Ellerbeck EF, Whittle JC, Mehr DR, et al. Fracture risk in nursing home residents initiating antipsychotic medications. J Am Geriatr Soc. 2013;61:715–22. doi: 10.1111/jgs.12216.
    1. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882–8. doi: 10.1001/archinte.165.16.1882.
    1. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210. doi: 10.1097/01.JGP.0000200589.01396.6d.
    1. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11:120–7. doi: 10.1016/j.jamda.2009.10.001.
    1. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7:492–500. doi: 10.1038/nrn1926.
    1. Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007;20:41–9. doi: 10.1177/0891988706292762.
    1. Rinaldi P, Spazzafumo L, Mastriforti R, Mattioli P, Marvardi M, Polidori MC, et al. Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study. Int J Geriatr Psychiatry. 2005;20:168–74. doi: 10.1002/gps.1267.
    1. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73. doi: 10.3389/fneur.2012.00073.
    1. Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722–7. doi: 10.1111/j.1532-5415.1986.tb04303.x.
    1. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170–7. doi: 10.1002/gps.1858.
    1. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Leitlinie Nr. 12: Demenz. Düsseldorf: omikron publishing; 2008.
    1. National Collaborating Centre for Mental Health. Dementia: A NICE–SCIE guideline on supporting people with dementia and their carers in health and social care. National Clinical Practice Guideline Number 42. Leicester: British Psychological Society; 2007.
    1. Cohen-Mansfield J. Nonpharmacologic treatment of behavioral disorders in dementia. Curr Treat Options Neurol. 2013;15:765–85. doi: 10.1007/s11940-013-0257-2.
    1. Kitwood T. Dementia reconsidered: the person comes first. Buckingham: Open University Press; 1997.
    1. Kitwood T. Demenz: Der person-zentrierte Ansatz im Umgang mit verwirrten Menschen. 6. Aufl. Bern: Hans Huber; 2013.
    1. Edvardsson D, Winblad B, Sandman PO. Person-centred care of people with severe Alzheimer’s disease: current status and ways forward. Lancet Neurol. 2008;7:362–7. doi: 10.1016/S1474-4422(08)70063-2.
    1. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess. 2014;18:1–226. doi: 10.3310/hta18610.
    1. Testad I, Corbett A, Aarsland D, Lexow KO, Fossey J, Woods B, et al. The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. Int Psychogeriatr. 2014;26:1083–98. doi: 10.1017/S1041610214000131.
    1. Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer’s disease: controversies and possible solutions. Curr Opin Psychiatry. 2009;22:532–40. doi: 10.1097/YCO.0b013e32833111f9.
    1. Howard R, Ballard C, O’Brien J, Burns A. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry. 2001;16:714–7. doi: 10.1002/gps.418.
    1. Richter T, Meyer G, Möhler R, Köpke S. Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database Syst Rev. 2012;12
    1. Fossey J, Masson S, Stafford J, Lawrence V, Corbett A, Ballard C. The disconnect between evidence and practice: a systematic review of person-centred interventions and training manuals for care home staff working with people with dementia. Int J Geriatr Psychiatry. 2014;29:797–807. doi: 10.1002/gps.4072.
    1. Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332:756–61. doi: 10.1136/bmj.38782.575868.7C.
    1. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN), in Zusammenarbeit mit der Deutschen Alzheimer Gesellschaft e.V. – Selbsthilfe Demenz. Interdisziplinäre S3-Praxisleitlinien: Diagnose- und Behandlungsleitlinie Demenz. Berlin: Springer; 2010.
    1. Menn P, Holle R, Kunz S, Donath C, Lauterberg J, Leidl R, et al. Dementia care in the general practice setting: a cluster randomized trial on the effectiveness and cost impact of three management strategies. Value Health. 2012;15:851–9. doi: 10.1016/j.jval.2012.06.007.
    1. Vollmar HC, Mayer H, Ostermann T, Butzlaff ME, Sandars JE, Wilm S, et al. Knowledge transfer for the management of dementia: a cluster randomised trial of blended learning in general practice. Implement Sci. 2010;5:1. doi: 10.1186/1748-5908-5-1.
    1. Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107:543–51.
    1. Fossey J, James I. Evidence-based approaches for improving dementia care in care homes. London: Alzheimer’s Society; 2008.
    1. A’s S. Optimising treatment and care for people with behavioural and psychological symptoms of dementia. London: A Best Practice Guide for Health and Social Care Professionals; 2011.
    1. Cohen-Mansfield J, Libin A, Marx MS. Non-pharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci. 2007;62:908–16. doi: 10.1093/gerona/62.8.908.
    1. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci. 1997;52:M369–77. doi: 10.1093/gerona/52A.6.M369.
    1. Giraudeau B, Ravaud P. Preventing bias in cluster randomised trials. PLoS Med. 2009;6 doi: 10.1371/journal.pmed.1000065.
    1. Palm R, Kohler K, Schwab CG, Bartholomeyczik S, Holle B. Longitudinal evaluation of dementia care in German nursing homes: the "DemenzMonitor" study protocol. BMC Geriatr. 2013;13:123. doi: 10.1186/1471-2318-13-123.
    1. Logsdon RG. QoL-AD - Germany/German - Version of 8 Jul 08. Lyon: Mapi Research Institute; 1996.
    1. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer’s disease: patient and caregiver reports. Journal of Mental Health & Aging. 1999;5:21–32.
    1. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64:510–9. doi: 10.1097/00006842-200205000-00016.
    1. Köhler L, Weyerer S, Schäufele M. Proxy screening tools improve the recognition of dementia in old-age homes: results of a validation study. Age Ageing. 2007;36:549–54. doi: 10.1093/ageing/afm108.
    1. Weyerer S, Schäufele M, Hendlmeier I, Kofahl C, Sattel H, Jantzen B, et al. Evaluation der Besonderen Stationären Dementenbetreuung in Hamburg. Bericht. Zentralinstitut für Seelische Gesundheit: Mannheim; 2004.
    1. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44:M77–84. doi: 10.1093/geronj/44.3.M77.
    1. Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI). The Research Institute of the Hebrew Home of Greater Washington: Rockville, Maryland; 1991.
    1. Cohen-Mansfield J. Assessment of agitation. Int Psychogeriatr. 1996;8:233–45. doi: 10.1017/S104161029600261X.
    1. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing and evaluating complex interventions: the new medical research council guidance. BMJ. 2008;337:a1655. doi: 10.1136/bmj.a1655.
    1. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: medical research council guidance. BMJ. 2015;350:h1258. doi: 10.1136/bmj.h1258.
    1. Grant A, Treweek S, Dreischulte T, Foy R, Guthrie B. Process evaluations for cluster-randomised trials of complex interventions: a proposed framework for design and reporting. Trials. 2013;14:15. doi: 10.1186/1745-6215-14-15.
    1. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. London: Arnold; 2000.
    1. International Conference on Harmonisation. Guideline for good clinical practice E6(R1), International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 1996.
    1. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. doi: 10.1001/jama.2013.281053.
    1. Verbeek H, Meyer G, Leino-Kilpi H, Zabalegui A, Hallberg IR, Saks K, et al. A European study investigating patterns of transition from home care towards institutional dementia care: the protocol of a right time place care study. BMC Public Health. 2012;12:68. doi: 10.1186/1471-2458-12-68.
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345 doi: 10.1136/bmj.e5661.
    1. Möhler R, Bartoszek G, Meyer G. Quality of reporting of complex healthcare interventions and applicability of the CReDECI list—a survey of publications indexed in PubMed. BMC Med Res Methodol. 2013;13:125. doi: 10.1186/1471-2288-13-125.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する